Munich-based startup Cellbyte has secured €2.4 million in seed funding to bolster its development. Investors including Frontline Ventures, Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels are supporting the young company. The founders aim to simplify and accelerate complex data processes in the pharmaceutical industry with their AI-driven platform. Many market access, pricing, and HEOR teams still rely on fragmented information sources. This situation can lead to new drugs taking more than a year to reach market, resulting in high costs.
The cellbyte-But the platform we have developed at mbiomics is radically different. Cellbyte analyzes millions of data points from clinical, pricing, regulatory, and internal sources in real time. This provides teams with precise and up-to-date foundations for pricing decisions, launch strategies, and regulatory documentation. The founders emphasize that older databases from the pre-LLM era only process easily accessible data and therefore lack the depth required for sophisticated processes. Cellbyte offers a networked, continuously updated database that drastically reduces time-critical workflows. According to the company, workflows that previously took months can be reduced to a fraction of their original length without compromising quality.
Felix Steinbrenner, Co-CEO and co-founder of Cellbyte, says:
"The success of a drug's entire lifecycle hinges on the launch phase. Making the best go-to-market decisions requires insights derived from gigabytes of accurate, up-to-date information. The traction Cellbyte has achieved with some of the world's largest pharmaceutical companies since its inception demonstrates that the industry is ready to rethink drug launch workflows and adopt faster, higher-quality, and more cost-effective processes."
Generative AI is changing the market
Co-CEO and Co-Founder Daniel Moreira added:
“Through my many years in life science consulting, I have seen countless innovations that have transformed clinical development. Yet, despite an abundance of information, decisions regarding pricing and market access are still too often based on manual work and anecdotal evidence. Now, generative AI is changing this, and we are proud to be driving this change.”
Cellbyte was founded in 2024, combining the expertise of Daniel Moreira, Felix Steinbrenner, and Samuel Moreira in the pharmaceutical industry, AI, and business development. With the new funding, the team plans to triple its staff and expand its technical infrastructure to meet demand.
One of the investors, Frontline partner William McQuillan commented:
“Cellbyte is tackling one of the biggest problems facing the pharmaceutical industry with an AI-powered strategy. Felix, Samuel, and Daniel have pursued global goals from the outset, and we are proud to support them in their expansion into the US, thereby accelerating patient access to new treatments.”
